Client: Medicines for Malaria Venture
Duration: 2017-2018
Region: Sub-Saharan Africa
Country: Zambia
Solutions: Global Health
Malaria is a serious public health problem in rural Zambia, particularly affecting children under 5. A variety of delays and barriers to successful treatment for severe malaria mean that incidence rates in Central Province between 2013 and 2015 were 495 per 1,000 children under 5 years.
The MAMaZ Against Malaria (MAM) project addressed the lack of access to quality commodities for case management of severe malaria in rural Zambia.
The project increased access to community-based pre-referral treatment for severe malaria for children from six months to under 6 years old, and to reduce referral delays from the community to health facilities that are equipped to treat severe malaria.
The goal of the project was to devise an evidence-based and sustainable strategy for improving the access of hard-to-reach communities to effective treatment for severe malaria.
The project generated evidence showing that it is feasible to provide pre-referral treatment for severe malaria in the communities and improve case management of severe malaria at lower-level health facilities.
MAM used a health systems and operational research approach to address the constraints that limit knowledge of severe malaria at community level and access to quality medical drugs which undermine effect case management.
RELATED CONTENT:
The Integrated Pharmaceutical and Supply Chain Technical Assistance Activity works to ensure more sustainable access to—and appropriate use of—quality-assured and affordable health commodities in Kenya by supporting the development of an increasingly resilient and mature supply chain system and pharmaceutical regulatory services.
Read More